Transamerica Financial Advisors LLC Acquires New Shares in Quest Diagnostics Incorporated $DGX

Posted by Geri Gentry on Aug 27th, 2026

Transamerica Financial Advisors LLC acquired a new position in Quest Diagnostics Incorporated (NYSE:DGX – Free Report) during the second quarter, HoldingsChannel.com reports. The institutional investor acquired 3,969 shares of the medical research company’s stock, valued at approximately $841,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Moneta Group Investment Advisors LLC grew its position in Quest Diagnostics by 3.7% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 1,387 shares of the medical research company’s stock worth $241,000 after purchasing an additional 50 shares during the last quarter. Ossiam boosted its position in shares of Quest Diagnostics by 6.1% during the third quarter. Ossiam now owns 1,059 shares of the medical research company’s stock worth $202,000 after buying an additional 61 shares during the period. Independent Advisor Alliance grew its holdings in Quest Diagnostics by 1.6% in the 4th quarter. Independent Advisor Alliance now owns 4,298 shares of the medical research company’s stock worth $746,000 after buying an additional 66 shares in the last quarter. Brown Advisory Inc. increased its position in Quest Diagnostics by 1.0% in the 4th quarter. Brown Advisory Inc. now owns 7,287 shares of the medical research company’s stock valued at $1,265,000 after acquiring an additional 71 shares during the period. Finally, Hantz Financial Services Inc. boosted its position in Quest Diagnostics by 9.6% during the 4th quarter. Hantz Financial Services Inc. now owns 835 shares of the medical research company’s stock worth $145,000 after acquiring an additional 73 shares during the period. 88.06% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, SVP Mark E. Delaney sold 1,600 shares of the stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $235.18, for a total value of $376,288.00. Following the completion of the transaction, the senior vice president owned 10,335 shares in the company, valued at $2,430,585.30. This trade represents a 13.41% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karthik Kuppusamy sold 8,147 shares of the business’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $200.00, for a total value of $1,629,400.00. Following the sale, the senior vice president owned 13,510 shares in the company, valued at approximately $2,702,000. The trade was a 37.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 19,747 shares of company stock valued at $3,947,088 over the last three months. Insiders own 0.88% of the company’s stock.

Quest Diagnostics Trading Up 0.1%

Shares of NYSE:DGX opened at $244.78 on Thursday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.46 and a current ratio of 1.59. The stock has a market capitalization of $27.02 billion, a price-to-earnings ratio of 25.99, a PEG ratio of 2.25 and a beta of 0.56. Quest Diagnostics Incorporated has a 1-year low of $171.18 and a 1-year high of $246.00. The company has a 50 day moving average price of $222.01 and a 200 day moving average price of $206.46.

Quest Diagnostics (NYSE:DGX – Get Free Report) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $3.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.82 by $0.30. The company had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $2.97 billion. Quest Diagnostics had a return on equity of 16.01% and a net margin of 9.18%.The firm’s revenue was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.62 earnings per share. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. On average, research analysts anticipate that Quest Diagnostics Incorporated will post 11.15 EPS for the current fiscal year.

Quest Diagnostics Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 21st. Stockholders of record on Tuesday, October 6th will be issued a dividend of $0.86 per share. This represents a $3.44 annualized dividend and a dividend yield of 1.4%. The ex-dividend date of this dividend is Tuesday, October 6th. Quest Diagnostics’s dividend payout ratio is currently 36.52%.

Analyst Upgrades and Downgrades

A number of research firms have commented on DGX. Robert W. Baird boosted their price target on shares of Quest Diagnostics from $236.00 to $255.00 and gave the stock a “neutral” rating in a research report on Friday, July 24th. JPMorgan Chase & Co. upped their target price on Quest Diagnostics from $220.00 to $250.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 28th. Wall Street Zen upgraded Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Tuesday, July 28th. UBS Group boosted their price objective on Quest Diagnostics from $220.00 to $232.00 and gave the stock a “neutral” rating in a research note on Friday, July 24th. Finally, Mizuho upped their price objective on Quest Diagnostics from $235.00 to $260.00 and gave the company an “outperform” rating in a report on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $235.31.

Read Our Latest Analysis on Quest Diagnostics

About Quest Diagnostics

(Free Report)

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.